BioPharma Drive: Drug Pricing

OCTOBER 24, 2024

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple shots on the market and in development.

Vaccine 162

Vaccine Marketing 162

BioPharma Drive: Drug Pricing

SEPTEMBER 13, 2024

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Vaccine 277

Vaccine Production Marketing 277

BioPharma Drive: Drug Pricing

SEPTEMBER 27, 2023

Despite the company's recent Phase 3 setbacks in RSV and COVID, CEO Paul Chaplin sees a path forward for the Dutch biotech in the travel vaccine market.

Vaccine 173

Vaccine Marketing 173

BioPharma Drive: Drug Pricing

OCTOBER 22, 2024

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.

Research 219

Research Vaccine Marketing 219

BioPharma Drive: Drug Pricing

SEPTEMBER 3, 2024

The company's value jumped by several billion dollars as trial results showed its experimental shot could match and, in some cases, even outperform Pfizer's market-leading Prevnar 20.

Vaccine 182

Vaccine Trials Marketing 182

SCIENMAG: Medicine & Health

MARCH 19, 2024

Credit: IVI IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E.

Vaccine 82

Vaccine Marketing International 82

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. Yet, the recent COVID-19 pandemic highlighted the obstacles that are inherent today in the development of vaccines. Stabilizers play a crucial role in maintaining the vaccine's potency and integrity throughout its shelf life.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

BioPharma Drive: Drug Pricing

AUGUST 14, 2023

The agency needs more time to settle with Valneva the design of a post-marketing study for the shot, which could become the first preventive therapy for chikungunya available in the U.S.

Vaccine 130

Vaccine FDA Therapies Marketing 130

The Pharma Data

AUGUST 7, 2020

AstraZeneca has signed its first deal in China to produce and deliver its vaccine candidate against COVID-19 in the country, partnering up with manufacturing firm Shenzhen Kangtai Biological Products. billion citizens in China, and the country is AstraZeneca’s biggest market. There are around 1.4

Vaccine 88

Vaccine Trials Marketing Production 88

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna, Inc.,

Vaccine 52

Vaccine Marketing RNA Science 52

Drug Target Review

DECEMBER 9, 2024

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors. With these exclusive rights, they can establish a competitive edge, control market entry, and potentially set higher prices due to the lack of competition.

Engineering 105

Engineering International Drug Development Science 105

PPD

JUNE 13, 2023

Clinical trials for COVID-19 vaccines changed how all vaccine trials are conducted. The success of the COVID-19 vaccines has brought renewed interest to vaccine development across indications and therapeutic areas. This increase in activity means the vaccine space will be fiercely competitive in the coming years.

Vaccine 52

Vaccine Clinical Trials Clinical Research Trials 52

Drug Patent Watch

DECEMBER 17, 2024

Contract Development and Manufacturing Organizations (CDMOs) are at the forefront of this shift, playing a crucial role in bringing innovative therapies to market. Responding to Market Demands The pharmaceutical market is notoriously unpredictable. Flexibility has become more than just a buzzword it’s a necessity.

Pharmaceuticals 90

Pharmaceuticals Therapies Production Pharmaceutical Companies 90

The Pharma Data

JUNE 24, 2021

The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Secondary objectives are to describe immune responses produced by each of the vaccines.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

EG Life Sciences

JUNE 2, 2022

At the most recent Bio-IT World conference , Barnhart shows how Agile practices not only bring products to market faster – they also save lives.

Vaccine 52

Vaccine Pharmaceuticals Marketing Production 52

The Pharma Data

JUNE 24, 2021

today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY ® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group.

Vaccine 52

Vaccine Clinical Trials Trials FDA 52

Predictive Oncology

APRIL 29, 2024

(NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2

Vaccine 52

Vaccine Marketing Drugs 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. The function of the adjuvant is to market the body’s immune reaction.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

JULY 23, 2021

government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country.

Vaccine 52

Vaccine Government Immune Response FDA 52

Advarra

JANUARY 11, 2024

While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

The Pharma Data

SEPTEMBER 5, 2021

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]). To date, AstraZeneca and its partners have supplied more than 1.1

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

JULY 21, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S. We are proud to deliver the first vaccine to help protect people in the U.S. 45 years ago.

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

Drug Target Review

MARCH 26, 2024

DGG: At Osivax, we’re working on a new class of vaccines that target invariant parts of mutating viruses; this approach is disruptive and very different from conventional vaccines. DGG: Vaccines are experiencing a revolution in the post-COVID era with the emergence of mRNA technology.

Vaccine 110

Vaccine Virus Immune Response Science 110

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 102

RNA Virus DNA Vaccine 102

The Pharma Data

NOVEMBER 17, 2021

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. 2) From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.(3,4,5,6,7).

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

Drug Target Review

SEPTEMBER 5, 2024

This was very challenging for me and at that moment I decided to get experience from later stage products and therefore took on the role as Global Product Director for late-stage marketed cardiovascular products. I got the opportunity to lead a biopharma company at Alzinova that are developing a vaccine candidate against Alzheimer’s disease.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

The Pharma Data

OCTOBER 6, 2021

Pfizer and BioNTech today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18?years years of age and older.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

APRIL 18, 2022

Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

OCTOBER 29, 2021

Food and Drug Administration (FDA) has authorized for exigency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 times of age ( also appertained to as 5 to< 12 times). For this age group, the vaccine is to be administered in a two- cure authority of 10-µg boluses given 21 days piecemeal. EligibleU.S. EligibleU.S.

Vaccine 52

Vaccine FDA Trials Government 52

The Pharma Data

JULY 29, 2021

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines. HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. President of the Global Vaccine Business Unit, Takeda. 2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.

Vaccine 52

Vaccine Clinical Trials Pharmaceutical Companies Virus 52

The Pharma Data

FEBRUARY 24, 2022

A vaccine manufactured in plants and developed in Canada. Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).

Vaccine 52

Vaccine Virus Government Disease 52